Compositions, methods and kits for reducing lipid levels
Compositions, methods, and kits useful for treating hyperlipidemic conditions are provided herein. Such compositions can contain synergizing amounts of nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites in combination with leucine and/or a leucine metabolite, with or without resveratrol.
1. A composition comprising:
a. at least 250 mg of leucine and/or at least 25 mg of one or more leucine metabolites, wherein the leucine metabolite is selected from the group consisting of keto-isocaproic acid (KIC), alpha-hydroxy-isocaproic acid, and hydroxymethylbutyrate (HMB); and
b. at least 1 mg of nicotinic acid and/or nicotinamide riboside and/or one or more nicotinic acid metabolites, wherein the nicotinic acid metabolite is selected from the group consisting of nicotinyl CoA, nicotinuric acid, nicotinate mononucleotide, nicotinate adenine dinucleotide, and nicotinamide adenine dinucleotide; and
wherein the composition is substantially free of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, valine, isoleucine and tyrosine.
2. The composition of claim 1 , wherein the composition is substantially free of nicotinamide.
3. The composition of claim 1 , wherein the component (a) in the composition is leucine and the component (b) in the composition is nicotinic acid.
4. The composition of claim 1 , wherein the amount of leucine and/or one or more leucine metabolites is less than about 1300 mg.
5. The composition of claim 1 , wherein the amount of nicotinic acid and/or nicotinamide riboside and/or one or more nicotinic acid metabolites is less than about 250 mg.
6. The composition of claim 1 , wherein the amount of nicotinic acid and/or nicotinamide riboside and/or one or more nicotinic acid metabolites is between about 1-100 mg.
7. The composition of claim 1 , wherein the composition further comprises resveratrol.
8. The composition of claim 1 , wherein the composition is a tablet, a capsule, or a pill.
9. The composition of claim 1 , wherein the composition contains less than about 10% of non-leucine amino acids.
10. The composition of claim 1 , further comprising one or more therapeutic agents is selected from the group consisting of HMG-CoA inhibitor, fibrate, bile acid sequestrant, ezetimibe, lomitapide, phytosterols, CETP antagonist, orlistat, and any combination thereof.
11. The composition of claim 1 wherein the composition is formulated in a unit dosage form.
12. A method of lowering total cholesterol level or total lipid content in a subject in need thereof, comprising administering to said subject the composition of claim 1 to effect a reduction in the total cholesterol level in the subject or total lipid content.
13. A composition comprising:
a. at least 250 mg of leucine and/or 25 mg of one or more leucine metabolites, wherein the leucine metabolite is selected from the group consisting of keto-isocaproic acid (KIC), alpha-hydroxy-isocaproic acid, and hydroxymethylbutyrate (HMB); and
b. at least 1 mg of nicotinic acid and/or nicotinamide riboside and/or one or more nicotinic acid metabolites, wherein the nicotinic acid metabolite is selected from the group consisting of nicotinyl CoA, nicotinuric acid, nicotinate mononucleotide, nicotinate adenine dinucleotide, and nicotinamide adenine dinucleotide;
wherein the molar ratio of component (a) to (b) in said composition is greater than 5, and
wherein the composition is substantially free of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, valine, isoleucine and tyrosine.
14. The composition of claim 13 , wherein the molar ratio of component (a) to (b) is less than about 100.
15. The composition of claims 13 , wherein the composition is substantially free of nicotinamide.
16. The composition of claims 13 , wherein the component (a) in the composition is leucine and the component (b) in the composition is nicotinic acid.
17. The composition of claims 13 , wherein the amount of leucine and/or one or more leucine metabolites is less than about 1300 mg.
18. The composition of claims 13 , wherein the amount of nicotinic acid and/or nicotinamide riboside and/or one or more nicotinic acid metabolites is between about 1-100 mg.
19. The composition of claims 13 , wherein a portion of the leucine and/or one or more leucine metabolites is in a free form.
20. The composition of claims 13 , wherein the composition is a tablet, a capsule, or a pill.
21. The composition of claims 13 wherein the composition is formulated in a unit dosage form.
22. A method of lowering total cholesterol level or total lipid content in a subject in need thereof, comprising administering to said subject the composition of claims 13 to effect a reduction in the total cholesterol level or total lipid content in the subject.